thiotepa

These results demonstrate that model-based ATG dosing promotes robust CD4+ immune reconstitution after ex vivo CD34+ selected allogeneic HCT, underscoring the potential of pharmacokinetically guided ATG as a strategy to optimise immune recovery in myeloablative, calcineurin inhibitor-free transplantation for haematological malignancies.

P2, N=40, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China

P1, N=60, Not yet recruiting, St. Jude Children's Research Hospital

Treatment with intrathecal pemetrexed via the Ommaya reservoir, combined with intravenous tislelizumab and carboplatin, resulted in 12 months of progression-free survival. For subsequent central nervous system progression involving both brain parenchymal metastasis and LM, we administered whole brain radiotherapy followed by second-line intrathecal thiotepa via Ommaya reservoir alongside tislelizumab and bevacizumab...Remarkably, the patient has survived nearly 29 months while maintaining good performance status and quality of life - to our knowledge, one of the longest reported survival for an NSCLC patient with LM harboring KRAS-G12V or other non-targetable mutations. This case suggests that combining ventriculoperitoneal shunt with Ommaya reservoir-delivered intrathecal chemotherapy may represent an effective therapeutic approach for LM patients.

As of June 2025, the patient has achieved a CR with a progression-free survival of 9 months before experiencing disease recurrence. This rare case of NF1-associated oligodendroglioma was managed with thiotepa, bevacizumab, teniposide, and tunlametinib, highlighting the potential of MEK inhibition in NF1-related gliomas.

P3, N=37, Not yet recruiting, Shanghai General Hospital; Shanghai General Hospital

P4, N=36, Not yet recruiting, Hangzhou First People's Hospital; Hangzhou First People's Hospital

P2, N=12, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Oct 2025 --> Oct 2026

He developed a posterior medulla relapse successfully salvaged with gemcitabine-paclitaxel-oxaliplatin, high-dose etoposide-thiotepa with autologous stem-cell transplantation, and craniospinal irradiation. When raised intracranial pressure precludes lumbar puncture, CSF sampling via EVD is a safe alternative. Coordinated oncologic-endocrine care supports durable disease control with tailored long-term hormonal follow-up.

P1, N=30, Recruiting, Dana-Farber Cancer Institute | N=20 --> 30 | Trial completion date: Dec 2030 --> Aug 2029 | Trial primary completion date: Dec 2029 --> Aug 2028

P3, N=91, Completed, Children's Oncology Group | Active, not recruiting --> Completed | Trial completion date: Dec 2028 --> Sep 2025

P2, N=31, Active, not recruiting, M.D. Anderson Cancer Center | Phase classification: P1 --> P2